Status: Not yet recruiting
Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors
This is a Phase 1b study to assess the safety and tolerability of STI-1386, an oncolytic virus, in subjects with relapsed and refractory solid tumors (RRSTs).
Participants needed: 36
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Sorrento Therapeutics, Inc.Updated: Apr 12, 2023
Eligibility criteria
Histologically confirmed extracranial solid tumors that are relapsing or refract... [+8]
Have a primary brain tumor [+17]